Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon

Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become availabl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Meyer, Douglas F., Tobias, Hillel, Min, Albert D., Rajendra, Arathi, Zic, Ivanka, Brettholz, Edward, Clain, David J., Klion, Franklin, Bernstein, David, Bodenheimer, Henry C.
Format: Artigo
Idioma:Inglês
Publicat: Hindawi Publishing Corporation 2010
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3003973/
https://ncbi.nlm.nih.gov/pubmed/21188197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2010/537827
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars